Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in …
WEB6 hours ago · VTYX. Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx ...
Ventyx Biosciences Announces $27 Million Strategic Investment …
WEB12 hours ago · Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX ...
Ventyx Biosciences Announces $27 Million Strategic Investment …
WEB1 day ago · The closing of the transaction is expected to occur on September 23, 2024. “We are very pleased with this strategic investment from Sanofi,” said Raju Mohan, Chief Executive Officer. “Sanofi is a global leader in immunological and inflammatory diseases, and we believe this transaction is a recognition that VTX3232 could potentially offer ...
Sanofi makes $27M equity investment in Ventyx
WEB9 hours ago · Ventyx has completed phase 1 testing in healthy adults that found daily doses of VTX3232 to be well-tolerated and tied to target coverage achieved in both plasma and cerebrospinal fluid levels, ...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a …
WEBSep 6, 2024 · In the first quarter of this year, we announced results from a Phase 1 trial of VTX3232 in adult healthy volunteers where steady-state exposures achieved with once-daily doses of VTX3232 exceeded the interleukin-1β (IL-1β) IC 90 in both plasma and cerebrospinal fluid over 24 hours. We believe these data support the …
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a …
WEBSep 6, 2024 · The Phase 2a trial of VTX3232 in early Parkinson’s disease is expected to enroll approximately ten patients for a 28-day open-label treatment period. The trial’s primary endpoint is safety and ...
Ventyx Biosciences Announces Positive Preclinical Data for CNS ...
WEBJun 5, 2024 · Improvements in cardiometabolic parameters were observed with VTX3232, including reductions in cholesterol, insulin resistance, fasting blood glucose and HbA1c. Systemic inflammatory biomarkers, including IL-1β, IL-6, and fibrinogen, were reduced in the plasma of VTX3232-treated DIO mice.
Ventyx Biosciences Announces Positive Preclinical Data for CNS ... - Nasdaq
WEBJun 5, 2024 · VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice. Additive effects were observed for VTX3232...
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
WEB12 hours ago · By Colin Kellaher. Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi ...
Ventyx Biosciences Announces Positive Topline Phase 1 Data
WEBJun 29, 2022 · The second candidate, VTX3232, is an orally bioavailable, CNS-penetrant NLRP3 inhibitor and belongs to a structurally distinct chemical series than VTX2735. VTX3232 is currently in IND-enabling...